Mastocytosis: all 77 studies
Page 1 of 1. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Analysis of the Role of IgE Proteoforms in Health and DiseaseRecruitingNCT07328178
- An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)RecruitingNCT07264959
- A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyRecruitingNCT07255638
- Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRecruitingNCT07143669
- Institutional Registry of Rare DiseasesRecruitingNCT06573723
- Mastocytosis Registry (of Zurich)RecruitingNCT06466889
- Relationship Between Circulating Sclerostin and Bone Lesions in Patients With MastocytosisRecruitingNCT06440148
- Angioedema Biomarker Research StudyRecruitingNCT06210698
- Epidemiological Data on Mast Cell Pathologies in FranceRecruitingNCT06186856
- Evaluation of the DALY on a Cohort of Patients With Indolent Systemic MastocytosisRecruitingNCT05923372
- Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
- Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisRecruitingNCT04655118Phase 2
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingNCT04333108Phase 3
- Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
- Study of Factors Regulating Mast Cell ProliferationRecruitingNCT00044122
- Topical Composition Therapy for the Treatment of Cutaneous MastocytosisTerminatedNCT04846348Phase 2Results posted
- COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedNCT04761822Phase 2Results posted
- Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic MastocytosisCompletedNCT03770273Phase 2Results posted
- Mast Cell Activation Test in Allergic DiseaseCompletedNCT03406325Results posted
- GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesTerminatedNCT03214666Phase 1/2Results posted
- Ibrutinib in Treating Patients With Advanced Systemic MastocytosisTerminatedNCT02415608Phase 2Results posted
- Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT01807598Phase 2Results posted
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
- Obatoclax for Systemic MastocytosisTerminatedNCT00918931Phase 2Results posted
- Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT00782067Phase 2Results posted
- Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
- Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaCompletedNCT00233454Phase 2Results posted
- A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic MalignanciesCompletedNCT00109707Phase 1/2Results posted
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
- Study of Cellular Heterogeneity in Patients With MastocytosisStatus unknownNCT06432556Not applicable
- Quality of Life and Disease-related Symptoms in Individuals With Systemic MastocytosisActive, not recruitingNCT06065007
- Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesTerminatedNCT05609942Phase 1
- Serum Basal Tryptase Levels in Healthy ChildrenCompletedNCT05323188
- Managed Access Programs for PKC412, MidostaurinNo longer availableNCT05219266
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisActive, not recruitingNCT05186753Phase 2
- Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement PatientsStatus unknownNCT05084872Phase 2/3
- Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)CompletedNCT04978740Not applicable
- Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMCompletedNCT04695431
- Assessment of Burden Disease in Patients With Mast Cell DisordersStatus unknownNCT04615663
- Improvement of Pigmented Skin Lesions in Patients With Mastocytosis After Performing 2 Sessions of Pigment LaserStatus unknownNCT04377828Not applicable
- Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerWithdrawnNCT03739606Phase 2
- Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French LanguageCompletedNCT03632811
- Mechanisms of Action of Photo(Chemo)Therapy in Skin DiseasesStatus unknownNCT03340155Not applicable
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002CompletedNCT02808793Phase 1
- Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline MutationsCompletedNCT02761473
- Mast Cell Connect: A Registry for Patients With MastocytosisCompletedNCT02620254
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesCompletedNCT02571036Phase 1
- (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesCompletedNCT02561988Phase 1
- The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom ImmunotherapyCompletedNCT02503800
- Treatment of Indolent Systemic Mastocytosis With PA101CompletedNCT02478957Phase 2
- Pregnancy and Medically Assisted Conception in Rare DiseasesWithdrawnNCT02450396
- Diagnostic Value of Bone Marrow Tryptase in Systemic MastocytosisCompletedNCT02441166Not applicable
- Patient-Reported Outcome Questionnaire for Systemic MastocytosisCompletedNCT02380222
- Midostaurin in Indolent Systemic MastocytosisStatus unknownNCT01920204Phase 2
- Cromoglicate in MastocytosisTerminatedNCT01701843Phase 2
- Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic MastocytosisStatus unknownNCT01602939Phase 2/3
- Study on Mastocytosis for Rupatadine TreatmentCompletedNCT01481909Phase 2/3
- Use of Tamoxifen in Systemic MastocytosisCompletedNCT01334996
- The Effect of Xolair ® (Omalizumab) in Mastocytosis PatientsCompletedNCT01333293Phase 2/3
- Imatinib in KIT-negative Systemic MastocytosisCompletedNCT01297777Phase 4
- Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V MutationCompletedNCT01266369Phase 2
- Evaluation of Response of Dasatinib to Treat MastocytosisStatus unknownNCT00979160Phase 2
- Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
- Masitinib in Severe Indolent or Smoldering Systemic MastocytosisCompletedNCT00814073Phase 3
- Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory DisordersTerminatedNCT00557895
- Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)CompletedNCT00493129Phase 2
- Efficacy and Safety of TF002 in Cutaneous MastocytosisCompletedNCT00457288Phase 2
- Molecular Mechanisms and Diagnosis of MastocytosisCompletedNCT00336076
- Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesCompletedNCT00171912Phase 2
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisCompletedNCT00132015Phase 2
- Cause and Natural Course of Pediatric-Onset MastocytosisCompletedNCT00050193
- Blood Factors in Mastocytosis and Unexplained Anaphylaxis and FlushingCompletedNCT00047918
- Stem Cell Transplantation to Treat Systemic MastocytosisCompletedNCT00006413Phase 2
- Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy IndividualsCompletedNCT00001760
- Study of Mast Cell PrecursorsCompletedNCT00001756
- Characteristics of Mast Cells in MastocytosisCompletedNCT00001356